Business Wire

CA-FORESCOUT

24.5.2022 14:02:05 CEST | Business Wire | Press release

Share
Forescout Launches Forescout Frontline to Help Organizations Tackle Ransomware and Real Time Threats

Forescout Technologies , the leader in automated cybersecurity, today announced the launch of Forescout Frontline , a new threat hunting service utilizing a team of highly-trained cybersecurity analysts to support cybersecurity teams by proactively identifying risks, enabling accelerated incident response, and maturing security posture. Forescout is offering this complimentary service for organizations that lack the internal resources and visibility to defend themselves from cybersecurity attacks, including ransomware and advanced persistent threats (APT).

“Cybersecurity attacks are on the rise. Simultaneously, cybersecurity teams are perennially understaffed and under resourced. This has created a perfect storm,” said Shawn Taylor, vice president of threat defense. “Organizations are under immense pressure to cope with the scale and speed of attacks and the havoc caused by the adversaries. Forescout is launching this new service to help organizations defend against attacks by providing a complete and holistic view of their assets.”

Many organizations use multiple security tools across multiple teams to help identify threats and risks. However, insights may be limited due to siloed views of IT, IoT, IoMT or OT assets. Typically, a variety of these asset types exist across an organization’s digital terrain and are often interconnected, which means cybersecurity risk must be identified and tackled holistically.

Delivered by Forescout Frontline analysts, the Threat Hunting and Risk Identification Service overcomes staffing resources and asset visibility challenges to uncover threats and identify risks that may otherwise remain undiscovered. Forescout Frontline will help organizations:

  • Discover, validate and prioritize a wide variety of cyber threats and vulnerabilities across all assets, including IT, IoT, IoMT and OT
  • Analyze the context and risk associated with all findings
  • Leverage the comprehensive insights to develop effective risk mitigation and remediation strategies

A State of Florida Agency, which supports several key Florida departments, engaged Forescout Frontline to understand each instance of Log4j, a zero-day vulnerability in a popular Java logging framework, across the organization’s 220 sites in 16 diverse divisions. In less than a day and a half, Forescout Frontline delivered insights into thousands of assets with vulnerabilities such as Log4j and Windows-based PrintNightmare. Additionally, hundreds of Critical CVSS-rated vulnerabilities affecting infrastructure devices such as switches and routers were found. Finally, actionable intelligence concerning critical embedded IoT TCP-IP stack-based instances such as NUCLEUS: 13 and RIPPLE 20, insecure communications, and other risks were also discovered. Leveraging this free service shrunk time to mitigation and remediation of these security gaps and improved overall security posture.

“When Log4J broke, we knew it was a critical issue, but we lacked a full picture of the risk within our extended enterprise. The [Forescout threat hunting] report was way more thorough than I expected, with in-depth information and actionable intelligence. Not just on Log4j but on other critical vulnerabilities as well, and not just in general terms but exactly where they exist in our environment.” – Information Security Manager, State of Florida Agency

Forescout Frontline levels the cybersecurity playing field by operationalizing the vulnerability research and threat intelligence produced by Forescout’s Vedere Labs and enhancing it with the Forescout Continuum Platform to provide threat hunting services across multiple dimensions. Forescout Frontline analysts include former public sector and private sector threat hunters with training in threat detection and incident response.

To learn more about Forescout Frontline, visit here , and for further insight into how a State of Florida agency benefitted from this new service, visit here.

About Forescout

Forescout Technologies, Inc. delivers automated cybersecurity across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types – IT, OT, IoT, IoMT. The Forescout Continuum Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets.

Managing cyber risk, together.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye